# A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

> **NCT07564596** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Climb Bio, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Systemic Lupus Erthematosus

## Interventions

- **DRUG:** Budoprutug

## Key facts

- **NCT ID:** NCT07564596
- **Lead sponsor:** Climb Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07564596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07564596, "A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07564596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*